ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

• Status: Withdrawn
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ophthotech Corporation
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Diagnosis of IPCV

• Patients must have had 3 sequential Eylea injections within the previous 4 months

Exclusion Criteria:

• Intravitreal treatment in the study eye prior to screening, regardless of indication, except 3 prior injections of Eylea

• History or evidence of severe cardiac disease

• Any major surgical procedure within one month of trial entry

• Subjects with a clinically significant laboratory value

• Any treatment with an investigational agent in the past 60 days for any condition

• Women who are pregnant or nursing

• Known serious allergies to the fluorescein dye, ICG dye, iodine, povidone iodine, or to the components or formulation of either Zimura or Eylea